A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
469actual
Sites
192
Countries
Argentina, Australia, Austria +27
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-18 | actual | When the study began enrolling |
| Primary completion | 2026-04-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-25 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prurigo Nodularis
Interventions
- Drug: Rocatinlimab — also filed as AMG 451
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFGlobal: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score at Week 24
measured Up to 24 weeks
US Only: Number of Participants Achieving Reduction from Baseline in Weekly Average of Daily Itch Score and Prurigo Nodularis Stage Assessment at Week 24
measured Up to 24 weeks
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed